No Data
Beijing Konruns Pharmaceutical (603590.SH): The late-stage esophageal squamous cell carcinoma stage III clinical study KC1036 is being conducted in an orderly manner according to plan.
Oct. 8th, Kangchen Pharmaceutical (603590.SH) stated during a specific research interview that KC1036 has made breakthroughs in clinical diversification, entering late-stage clinical research for stage Ⅲ esophageal squamous cell carcinoma. KC1036 is a multi-target receptor tyrosine kinase inhibitor independently developed by the company, and is systematically conducting multiple clinical trials as planned, with a focus on treating late-stage esophageal squamous cell carcinoma in clinical research for stage Ⅲ, maintaining local late-stage or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with PD-1 antibodies, and treating late-stage EWING sarcoma in adolescents aged 12 and above.
Kangchen Pharmaceutical 2024 Semi-Annual Report
Summary of Kangchen Pharmaceutical\'s 2024 Semi-Annual Report
Beijing Konruns Pharmaceutical (603590.SH) released its performance for the first half of the year, with a net income of 79.2028 million yuan, a decrease of 14.73% compared to the same period last year.
Beijing Konruns Pharmaceutical (603590.SH) released its 2024 interim report, with the company achieving revenue of 4...
Beijing Konruns Pharmaceutical (603590.SH): net income in the first half of the year was 79.2028 million yuan, a decrease of 14.73% year on year.
On August 27th, Beijing Konruns Pharmaceutical (603590.SH) released its semi-annual report. From January to June 2024, the company achieved revenue of 405.0249 million yuan, a decrease of 10.16% compared to the same period last year. The net income attributable to the owners of the parent company was 79.2028 million yuan, a decrease of 14.73% compared to the same period last year. The net income attributable to the owners of the parent company, excluding non-recurring losses and gains, was 74.4971 million yuan, a decrease of 12.18% compared to the same period last year.
Beijing Konruns Pharmaceutical (603590.SH): Sun Yuping resigned from the position of secretary to the board and financial director.
Beijing Konruns Pharmaceutical (603590.SH) announced that the board of directors recently received a letter from Sun Yu, the secretary of the board of directors and the chief financial officer, stating that he is unable to continue to perform his duties due to personal reasons. The board of directors expressed their respect and understanding, and agreed to Mr. Sun's resignation.
No Data
No Data